An Open-Label, Phase 2a Study to Evaluate the Pharmacodynamics of Different Dosing Regimens of TAK-448, a Kisspeptin Agonist, in Male Overweight/Obese Participants With Hypogonadotropic Hypogonadism
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2017
At a glance
- Drugs TAK 448 (Primary)
- Indications Hypogonadism
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Takeda
- 13 Feb 2017 Status changed to discontinued because the study did not achieve the primary efficacy objective.
- 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
- 10 Nov 2015 Obese Type 2 Diabetes Mellitus Subjects With Hypogonadotropic Hypogonadism are excluded from this trial as per ClinicalTrials.gov record. Accordingly changes in title, inclusion-exclusion criteria and purpose .